VACC - Vaccitech plc Stock Price, Fair Value and News

$4.95-71.95 (-93.56%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VACC Price Action

VACC RSI Chart

VACC Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-53.4

Price/Sales (Trailing)

3.9K

EV/EBITDA

-56.4

Price/Free Cashflow

-49.76

VACC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VACC Fundamentals

VACC Revenue

Revenue (TTM)

802.0K

Rev. Growth (Yr)

8.9K%

VACC Earnings

Earnings (TTM)

-57.8M

Earnings Growth (Yr)

42.34%

Earnings Growth (Qtr)

52.11%

VACC Profitability

EBT Margin

-7325.31%

Return on Equity

-36.31%

Return on Assets

-30.65%

Free Cashflow Yield

-2.01%

VACC Investor Care

Shares Dilution (1Y)

4.31%

Diluted EPS (TTM)

-1.48

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	33.7M	22.8M	11.8M	802.0K
2022	18.3M	27.1M	35.9M	44.7M
2021	4.3M	3.9M	623.0K	9.4M
2020	0	0	0	4.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Vaccitech plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

CEO	Mr. William J. Enright MBA
WEBSITE	vaccitech.co.uk
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	33

Vaccitech plc Frequently Asked Questions

What is the ticker symbol for Vaccitech plc? What does VACC stand for in stocks?

VACC is the stock ticker symbol of Vaccitech plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaccitech plc (VACC)?

As of Thu Oct 31 2024, market cap of Vaccitech plc is 3.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VACC stock?

You can check VACC's fair value in chart for subscribers.

Is Vaccitech plc a good stock to buy?

The fair value guage provides a quick view whether VACC is over valued or under valued. Whether Vaccitech plc is cheap or expensive depends on the assumptions which impact Vaccitech plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VACC.

What is Vaccitech plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Oct 31 2024, VACC's PE ratio (Price to Earnings) is -53.4 and Price to Sales (PS) ratio is 3.85 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VACC PE ratio will change depending on the future growth rate expectations of investors.